Life Science News

Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: ATURF) (FSE: AHUH) ("Sixth Wave" or the "Company") announces that its common shares, previously trading on the OTC Market under the symbol ATURF, are to commence trading on the OTC Market under the symbol SIXWF with effect July 6, 2021.

The Company's common shares will continue to trade under the symbol SIXW on the Canadian Securities Exchange.

No action is required by current shareholders in connection with this change.

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our website at: www.sixthwave.com.

ON BEHALF OF THE BOARD OF DIRECTORS

"Jonathan Gluckman"
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:

Phone: (801) 582-0559
E-mail: info@sixthwave.com

Cautionary Notes

This press release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the company's technologies are subject to the risks that the technologies may not prove to be effective, the uncertainty of medical product development, the uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if the patent is not granted. The Company has not yet completed the development of a prototype for the product that is subject to its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/89391

News Provided by Newsfile via QuoteMedia

Clene to Host VISIONARY-MS Results Call and Webcast on August 15

Clene to Host VISIONARY-MS Results Call and Webcast on August 15

Clene Inc. (NASDAQ: CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will present results from its Phase 2 VISIONARY-MS trial at 7:30 a.m. EDT on Monday, August 15.

Conference Call and Webcast Details:
Presentation Time: 7:30 a.m. EDT on August 15, 2022
Investors (Toll free): 1 (888) 770-7152
Conference ID: 5318408
Webcast link

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Eupraxia Pharmaceuticals Reports Second Quarter 2022 Financial Results

Eupraxia Pharmaceuticals Reports Second Quarter 2022 Financial Results

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the second quarter ended June 30, 2022 . All amounts are expressed in Canadian dollars unless otherwise indicated.

"Enrollment for our Phase 2 clinical trial, which is evaluating EP-104IAR's safety and efficacy for the treatment of pain due to osteoarthritis of the knee, continued as anticipated during the second quarter, and trial timelines remain on track for data readout in the first quarter of 2023," said Dr. James Helliwell , CEO of Eupraxia. "In addition, we significantly strengthened our financial position in the quarter by completing a financing for gross proceeds of $14.7 million . We believe we are well capitalized going forward to continue executing our Phase 2 clinical trial, while focussing on the diversification of our innovative drug delivery technology platform into other targeted therapeutic areas."

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming. The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following the investigational new drug candidate SYNB1353 for the potential treatment of homocystinuria (HCU).

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities in Rwanda

Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities in Rwanda

Collaboration aims to leverage innovative biosecurity capabilities to promote global health security and accelerate the development of the regional bioeconomy

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Rwanda Development Board ("RDB"), representing the government of the Republic of Rwanda today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent of developing and implementing new biosecurity capabilities in Rwanda .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.

Dear Fellow Shareholders:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program

CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program

First paragraph, first sentence of release should read: Cybin Inc. ( NEO: CYBN ) (NYSE American: CYBN) (" Cybin " or the " Company "), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics TM ", announced today that it has established an at-the-market equity program (the " ATM Program ") that allows Cybin to issue and sell up to USD$35,000,000 of common shares (Instead of Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (" Cybin " or the " Company "), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics TM ", announced today that it has established an at-the-market equity program (the " ATM Program ") that allows Cybin to issue and sell up to USD$35,000,0000 of common shares).

The updated release reads:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×